NCT07408869Visszavonva1. fázis
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 22.
Megadott ok: Sponsor decision
Rövid összefoglaló (regiszter, angolul)
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
- Állapot (regiszter)
- Visszavonva
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 0 (tényleges)
- Első benyújtás
- 2025. dec. 23.
- Kezdés
- 2026. ápr.
- Elsődleges befejezés
- 2026. dec.
- Fő szponzor
- Candid Therapeutics
- Betegségek
- Asztma, Atópiás dermatitisz (ekcéma)
- NCT-szám
- NCT07408869
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Current use of any allergen immunotherapy.
- Receipt of or inability to discontinue any excluded therapies
- Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period
- Blood donation or significant blood loss within 30 days prior to screening
Más betegség
- Elevated IgE levels for reasons other than the IgE mediated diseases
- Planned ingestion of food items to which they are allergic for the duration of the study (for food allergy patients)
- Active infection
- Serious mental illness, drug or alcohol abuse, dementia, or other condition that impair ability to sign ICF
- History of primary immunodeficiency
- History of CNS disease
- History of poorly controlled diabetes, chronic kidney disease, chronic pulmonary disease, uncontrolled cardiovascular disease, history of malignancy within 5 years
- History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug
- A history of severe allergic or anaphylactic reactions related to the underlying IgE mediated disease
Laborértékek
- Inadequate clinical laboratory parameters at Screening
Egyéb
- Individuals whose allergen exposures in their home and/or work environments may be expected to change significantly during the trial period
- Individuals who will decline blood products
- Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
- Individuals considered to be part of a vulnerable population (eg, incarceration)
- Individuals that in the opinion of the Investigator, are not suitable for participation in the trial
- Inability to comply with protocol-mandated requirements
Kiket keres a vizsgálat
- Patient meets at least one of the following:
- History of documented (skin prick test, in vitro testing, or food challenge), ongoing, IgE-mediated allergy to food (eg, peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp) with Screening total IgE ≥ 400 IU/mL
- Diagnosis of chronic rhinosinusitis with Screening total IgE > ULN
- Diagnosis of allergic rhinitis with Screening total IgE > ULN
- Diagnosis of asthma and classified as well controlled per 2024 Global Initiative for Asthma guidelines with Screening total IgE > ULN
- Diagnosis of chronic spontaneous urticaria with symptoms (eg, wheals or angioedema) for at least 6 weeks any time prior to screening and Screening total IgE > ULN
- Diagnosis of atopic dermatitis that has been present for at least 6 months before the screening visit and with Screening total IgE > ULN
- Agree to the use of highly effective contraception
Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Nucleus Network | Melbourne | Ausztrália | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.